During long-term interferon alpha-2b (IFN) therapy of Philadelphia chromosome-positive chronic myelogenous leukemia (CML) patients, short-term effects of tumor necrosis factor alpha (TNF) on peripheral leukocyte counts, as well as cortisol and corticotropin (ACTH) release were studied. TNF (40-160 micrograms/m2) was given as a 2-h infusion on 5 consecutive days every 3 weeks, in addition to s.c. daily IFN injections (4 mio U/m2), to four (two male/two female) patients, who had been treated for more than 8 months with IFN and additionally for 0-7 months with TNF. Leukocyte counts, cortisol, and ACTH were determined at 30-min intervals between 4 p.m. and midnight. Profiles were determined the day before and on day 1 of TNF therapy. Leukocyte numbers decreased 30 min after start of TNF administration and increased 30-60 min later with a rebound until the next TNF application. The increase of leukocyte counts was due mostly to neutrophil granulocytes. ACTH levels increased 30 min, cortisol 60 min, and leukocyte counts 90 min after start of TNF infusion. Metopirone, an inhibitor of cortisol synthesis given to one patient, suppressed the TNF-induced stimulation of cortisol secretion and subsequent increase of leukocyte counts, while ACTH blood levels were enhanced. It was concluded that leukocyte count increases after TNF/IFN administration might be related to TNF-evoked cortisol secretion.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/BF01695809 | DOI Listing |
Front Endocrinol (Lausanne)
January 2025
Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, China.
Objective: The C-reactive protein/Lymphocyte Ratio (CLR) is a novel biomarker whose role in the development of chronic kidney disease (CKD) is not well understood. This study aimed to investigate the correlation between CLR and the prevalence of CKD.
Methods: This cross-sectional study included participants from the US National Health and Nutrition Examination Survey conducted between 1999 and 2010.
Parasit Vectors
January 2025
Faculty of Information Technology, Mutah University, Mutah, Jordan.
Background: Amebiasis represents a significant global health concern. This is especially evident in developing countries, where infections are more common. The primary diagnostic method in laboratories involves the microscopy of stool samples.
View Article and Find Full Text PDFJ Med Microbiol
January 2025
Midwifery Education Programme, Faculty of Health Sciences, Dr. Soebandi University, Jember, Indonesia.
Anaemia and thrombocytopenia are blood-related irregularities linked to an increased likelihood of disease progression, leading to death in people living with human immunodeficiency virus 1 (PLHIV). Severe clinical conditions associated with human immunodeficiency 1 (HIV-1) infection may be related to blood irregularities among PLHIV. The study aimed to examine the factors correlated with blood irregularities among PLHIV receiving antiretroviral treatment in West Papua.
View Article and Find Full Text PDFJ Clin Hypertens (Greenwich)
January 2025
Department of Cardiology, Fifth Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.
The platelet-to-lymphocyte ratio (PLR) has been proposed as a promising inflammatory biomarker, with potential implications for cardiovascular prognosis. However, its association with mortality outcomes in hypertensive individuals is not fully elucidated. This investigation sought to clarify the linkage between PLR and both overall and cardiovascular mortality in hypertensive individuals.
View Article and Find Full Text PDFFront Microbiol
January 2025
Institute of Animal Husbandry and Veterinary Medicine, Beijing Academy of Agriculture and Forestry Sciences, Beijing, China.
Bovine viral diarrhea virus (BVDV) is the causative agent of bovine viral diarrhea, which causes significant economic loss to the global livestock industry. Despite the widespread use of inactivated BVDV vaccines, highly pathogenic strains continue to emerge. In China, regional variations in BVDV subtypes, morbidities, and symptoms, however, only the BVDV 1a subtype vaccine is currently approved.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!